Full Press Release Details
aflibercept 8 mg bla for treatment of wet age related macular degeneration and diabetic macular edema accepted for fda priority review.
REGN
aflibercept 8 mg bla for treatment of wet age related macular degeneration and diabetic macular edema accepted for fda priority review
Key Takeaway: aflibercept 8 mg bla for treatment of wet age related macular degeneration and diabetic macular edema accepted for fda priority review